King Pharmaceuticals KG
-
VHT Vanguard Health Care ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… acquisition of Genzyme, Merck of Germany's takeover of Millipore, and Pfizer's PFE acquisition of pain drugmaker King Pharmaceuticals . In our view, an ETF makes a lot of sense for health-care investors. No matter how deep your knowledge of …
-
IXJ iShares S&P Global Healthcare ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… acquisition of Genzyme, Merck of Germany's takeover of Millipore, and Pfizer's PFE acquisition of pain-drug maker King Pharmaceuticals . In our view, an ETF makes a lot of sense for health-care investors. No matter how deep your knowledge of …
-
RXL ProShares Ultra Health Care ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… acquisition of Genzyme, Merck of Germany's takeover of Millipore, and Pfizer's PFE acquisition of pain-drug maker King Pharmaceuticals . In our view, an ETF can help health-care investors diversify away company-specific risks. Granted, all …
-
Forbes' Matthew Herper notes that the CEO of Fougera, which Novartis is buying for $1.525B, is Brian Markison, who was CEO of King Pharmaceuticals when it was sold to Pfizer for $3.6B in 2010. Herper ...
… Herper notes that the CEO of Fougera, which Novartis is buying for $1.525B , is Brian Markison, who was CEO of King Pharmaceuticals when it was sold to Pfizer for $3.6B in 2010. Herper speculates that Markison won't be short of job offers …
-
PPH Market Vectors Pharmaceutical ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… acquisition of Genzyme, Merck of Germany's takeover of Millipore, and Pfizer's PFE acquisition of pain-drug maker King Pharmaceuticals . In our view, an ETF makes a lot of sense for health-care investors. No matter how deep your knowledge of …
-
XPH SPDR S&P Pharmaceuticals ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… acquisition of Genzyme, Merck of Germany's takeover of Millipore, and Pfizer's PFE acquisition of pain drugmaker King Pharmaceuticals . In our view, an ETF makes a lot of sense for health-care investors. No matter how deep your knowledge of …
-
PJP PowerShares Dynamic Pharmaceuticals ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… acquisition of Genzyme, Merck of Germany's takeover of Millipore, and Pfizer's PFE acquisition of pain-drugmaker King Pharmaceuticals . In our view, an ETF makes a lot of sense for health-care investors. No matter how deep your knowledge of …
-
IHE iShares Dow Jones US Pharmaceuticals ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… purchase of Genzyme, Merck of Germany's takeover of Millipore, and Pfizer's PFE acquisition of pain-drug maker King Pharmaceuticals . In our view, an ETF makes a lot of sense for health-care investors. No matter how deep your knowledge of …
-
Investment Advice from Your Uncle Polonius
… Mylan's MYL failed attempt to purchase King Pharmaceuticals KG . Mylan needs a salesforce, which the loudly opposed King acquisition was expected to deliver ..... the generic industry. Low costs are king in that business, and branded companies …
-
Covidien to Spin Out Pharmaceutical Business
… based on our review of some of its peers, such as Endo Pharmaceuticals ENDP, as well as the recent acquisition of King Pharmaceuticals by Pfizer PFE and Bristol-Myers Squibb's BMY sale of its imaging business (which included branded Cardiolite …